WO2011063774A3 - Pectin complexes of steroids and pharmaceutical compositions based thereon - Google Patents

Pectin complexes of steroids and pharmaceutical compositions based thereon Download PDF

Info

Publication number
WO2011063774A3
WO2011063774A3 PCT/CZ2010/000120 CZ2010000120W WO2011063774A3 WO 2011063774 A3 WO2011063774 A3 WO 2011063774A3 CZ 2010000120 W CZ2010000120 W CZ 2010000120W WO 2011063774 A3 WO2011063774 A3 WO 2011063774A3
Authority
WO
WIPO (PCT)
Prior art keywords
pectin
steroids
pharmaceutical compositions
compositions based
active substance
Prior art date
Application number
PCT/CZ2010/000120
Other languages
French (fr)
Other versions
WO2011063774A2 (en
Inventor
Vladimir Kral
Zbynek Oktabec
Josef Jampilek
Tomas Pekarek
Bohumil Proksa
Jiri Dohnal
Anna Malovikova
Anna Ebringerova
Anna Rezacova
Original Assignee
Zentiva, K.S.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zentiva, K.S. filed Critical Zentiva, K.S.
Publication of WO2011063774A2 publication Critical patent/WO2011063774A2/en
Publication of WO2011063774A3 publication Critical patent/WO2011063774A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin

Abstract

The present solution relates to a method of manufacturing a pharmaceutical composition containing an active substance in the form of an adduct (complex) with a pectin, optionally in a mixture with a glucan. The resulting adduct is characterized by higher solubility in water as compared with the original pharmaceutically active substance. The adduct (complex) consisting of the active substance and pectin is then used for preparing a dosage form with targeted (controlled) release in the intestine.
PCT/CZ2010/000120 2009-11-25 2010-11-25 Pectin complexes of steroids and pharmaceutical compositions based thereon WO2011063774A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CZ20090790A CZ302789B6 (en) 2009-11-25 2009-11-25 Method of increasing solubility of pharmaceutically active compounds and targeted (controlled) transport thereof into intestine
CZPV2009-790 2009-11-25

Publications (2)

Publication Number Publication Date
WO2011063774A2 WO2011063774A2 (en) 2011-06-03
WO2011063774A3 true WO2011063774A3 (en) 2012-01-19

Family

ID=43743524

Family Applications (3)

Application Number Title Priority Date Filing Date
PCT/CZ2010/000120 WO2011063774A2 (en) 2009-11-25 2010-11-25 Pectin complexes of steroids and pharmaceutical compositions based thereon
PCT/CZ2010/000122 WO2011063776A2 (en) 2009-11-25 2010-11-25 Soluble beta-glucan-api complexes for pharmaceutical use
PCT/CZ2010/000121 WO2011063775A2 (en) 2009-11-25 2010-11-25 Pectin complexes of sartans and pharmaceutical compositions based thereon

Family Applications After (2)

Application Number Title Priority Date Filing Date
PCT/CZ2010/000122 WO2011063776A2 (en) 2009-11-25 2010-11-25 Soluble beta-glucan-api complexes for pharmaceutical use
PCT/CZ2010/000121 WO2011063775A2 (en) 2009-11-25 2010-11-25 Pectin complexes of sartans and pharmaceutical compositions based thereon

Country Status (2)

Country Link
CZ (1) CZ302789B6 (en)
WO (3) WO2011063774A2 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105264080B (en) 2013-04-27 2020-02-07 加利福尼亚大学董事会 Fluxing agent for preparing reactive intermediates from biomass
CN103622928A (en) * 2013-11-27 2014-03-12 广西大学 Preparation method and application of pectin-base carrier material
CA3072198C (en) 2017-08-30 2023-07-04 Antares Pharma, Inc. Testosterone ester triglyceride formulations

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5505966A (en) * 1990-07-04 1996-04-09 Kabi Pharmacia Ab Therapeutical composition and process for its preparation
US5849327A (en) * 1994-07-29 1998-12-15 Advanced Polymer Systems, Inc. Delivery of drugs to the lower gastrointestinal tract
US20060188530A1 (en) * 1998-07-24 2006-08-24 Yoo Seo H Bile preparations for gastrointestinal disorders

Family Cites Families (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4950689A (en) 1987-03-31 1990-08-21 Yang Robert K Pectin delivery system
CA2014244A1 (en) * 1989-04-13 1990-10-13 Takeda Chemical Industries, Ltd. Stabilized composition of anthracyclines
US5032401A (en) * 1989-06-15 1991-07-16 Alpha Beta Technology Glucan drug delivery system and adjuvant
GB9004950D0 (en) * 1990-03-06 1990-05-02 Kelco Int Ltd Controlled release formulation
RO107187B1 (en) 1992-02-11 1993-10-29 Icn Galenika Sa Antiacid stabilized pharmaceutical composition and preparation process therefor
HU213872B (en) * 1993-09-08 1997-11-28 Mta Koezponti Kemiai Kutato In Oligo- and polygalacturonate mixed complex, pharmaceutical and food compositions containing them, further process for preparing these compounds
KR0121127B1 (en) 1994-05-09 1997-11-13 강박광 Transdermal drug delivery system having ionic polymer network
EP0876142B1 (en) * 1996-01-16 2001-09-26 Advanced Polymer Systems, Inc. Topical delivery of drugs to the lower gastrointestinal tract
IT1282381B1 (en) 1996-04-29 1998-03-20 Trans Bussan S A NEW FORMULATIONS OF DIACEREIN, OBTAINED BY INCLUSION OF THE ACTIVE INGREDIENT IN HYDROGEL POLYSACCHARIDES
EP0954260A1 (en) 1996-05-22 1999-11-10 Diversified Pharmaceuticals, Inc. Compositions, methods and devices for the transdermal delivery of drugs
US5891441A (en) 1996-07-08 1999-04-06 Diaz; Jose A. Chemical composition and method for more rapidly aiding the absorption, binding an elimination of undigested fat in the human body
US6200574B1 (en) 1996-07-08 2001-03-13 Jose A. Diaz Chemical composition for aiding the absorption, binding and elimination of undigested fat
FR2752843B1 (en) * 1996-08-30 1998-10-16 Sod Conseils Rech Applic CROSSLINKED COPOLYMERS BASED ON POLYCARBOXYLIC POLYMERS AND THEIR USE AS SUPPORTS OF PHARMACEUTICAL COMPOSITIONS
GB9707934D0 (en) 1997-04-18 1997-06-04 Danbiosyst Uk Improved delivery of drugs to mucosal surfaces
US20040136961A1 (en) 1997-10-09 2004-07-15 Ales Prokop Nanoparticulate composition for efficient gene transfer
US6337091B1 (en) * 1997-10-27 2002-01-08 Temple University - Of The Commonwealth System Of Higher Education Matrix for controlled delivery of highly soluble pharmaceutical agents
DE69831421T2 (en) 1997-12-02 2006-06-22 Archimedes Development Ltd. COMPOSITIONS FOR NASAL ADMINISTRATION
US6313103B1 (en) 1998-05-13 2001-11-06 Carrington Laboratories, Inc. Pectic substance as a growth factor stabilizer
KR20000011247A (en) 1998-07-23 2000-02-25 김윤 Composition and pharmaceutical dosage form for colonic drug delivery using polysaccharides
GB9822170D0 (en) 1998-10-13 1998-12-02 Danbioyst Uk Ltd Novel formulations of fexofenadine
RU2169002C2 (en) 1999-04-19 2001-06-20 Пятигорская государственная фармацевтическая академия Method of preparing inulin-pectin concentrate powder for medicinal and food aims from dried raw
US20020119928A1 (en) 2000-10-27 2002-08-29 Mcanalley Bill H. Dietary supplement compositions
US20030157161A1 (en) * 2001-05-01 2003-08-21 Angiotech Pharmaceuticals, Inc. Compositions and methods for treating inflammatory conditions utilizing protein or polysaccharide containing anti-microtubule agents
WO2003004033A1 (en) 2001-07-06 2003-01-16 Penwest Pharmaceuticals Company Sustained release formulations of oxymorphone
DE60206940T2 (en) 2001-09-03 2006-04-20 Dsm Ip Assets B.V. COMPOSITIONS CONTAINING PECTIC AND ASCORBIC ACID
JP2003127783A (en) 2001-10-25 2003-05-08 Mitsuboshi Belting Ltd Floor console
DE10212553A1 (en) 2002-03-16 2003-09-25 Knoell Hans Forschung Ev Acceleration of the biodegradation of porous wound coverings based on polyhydroxyalkanoate and polyanionic hydrocolloids is effected using a buffered formulation containing a poly-(hydroxybutyrate)-depolymerase
US7666876B2 (en) 2002-03-19 2010-02-23 Vernalis (R&D) Limited Buprenorphine formulations for intranasal delivery
AU2002244881A1 (en) 2002-03-22 2003-10-08 Ranbaxy Laboratories Limited Controlled release drug delivery system of pravastatin
DE10214005A1 (en) 2002-03-27 2003-10-09 Volker Bartz Orally administered dietetic, nutritional supplement or medicament composition, useful as hypolipemic agent, comprising mixture of pectin and/or guar powder with eicosapentaenoic and docosahexaenoic acids
DE20205184U1 (en) 2002-03-27 2002-12-19 Bartz Volker Blood lipid lowerers for oral use
DE10250083A1 (en) 2002-06-17 2003-12-24 Gruenenthal Gmbh Dosage form protected against abuse
KR100522239B1 (en) * 2002-07-16 2005-10-18 주식회사 서울제약 Compositions for controlled release acetaminophen dosage forms
JP2004059440A (en) 2002-07-25 2004-02-26 Mikasa Seiyaku Co Ltd Skin roughening preventing and mucosal repair agent
US20040087514A1 (en) 2002-09-06 2004-05-06 Hughes Thomas E Nutritional compositions
JP2004107295A (en) 2002-09-20 2004-04-08 National Agriculture & Bio-Oriented Research Organization Histamine release inhibitor
US6703044B1 (en) 2002-10-25 2004-03-09 Dexcel Pharma Tech, Ltd Venlafaxine formulations
CZ296475B6 (en) 2002-12-09 2006-03-15 Mikrobiologický Ústav Av Cr Fermentation process and isolation of extracellular glucan using Claviceps species fungi
GB0300531D0 (en) 2003-01-10 2003-02-12 West Pharm Serv Drug Res Ltd Pharmaceutical compositions
US20040241223A1 (en) 2003-05-27 2004-12-02 David Wong Oral dosage forms for macromolecular drugs
CN100477999C (en) 2003-12-29 2009-04-15 湖南华纳大药厂有限公司 Dispersible tablet of colloid petcin
IL160095A0 (en) 2004-01-28 2004-06-20 Yissum Res Dev Co Formulations for poorly soluble drugs
WO2005084648A1 (en) * 2004-02-27 2005-09-15 Ranbaxy Laboratories Limited Pharmaceutical compositions comprising candesartan cilexetil
WO2005084703A1 (en) 2004-03-09 2005-09-15 Nrl Pharma, Inc. Sustained-release composition for oral cavity
DE102004019916A1 (en) 2004-04-21 2005-11-17 Grünenthal GmbH Anti-abuse drug-containing patch
WO2005105040A2 (en) 2004-04-26 2005-11-10 Micelle Products, Inc. Water-soluble formulations of fat soluble vitamins and pharmaceutical agents and their applications
WO2006002106A2 (en) 2004-06-22 2006-01-05 Pro-Pharmaceuticals, Inc. Compositions and methods for the co-delivery of anti-cancer drugs, anti-angiogenic drugs, and a polysaccharide
US20070224148A1 (en) * 2004-08-13 2007-09-27 Symrise Gmbh & Co. Kg Beta-(1,3)-Beta-(1,4)-Glucan as Carrier for Chemical Substances
CN101128187A (en) * 2005-02-09 2008-02-20 达沃尔泰拉公司 Colonic delivery of active agents
ITBO20050123A1 (en) 2005-03-07 2005-06-06 Alfa Wassermann Spa GASTRORESISTIC PHARMACEUTICAL FORMULATIONS CONTAINING RIFAXIMINA
JP2008540602A (en) 2005-05-18 2008-11-20 ダ・ボルテラ Adsorbent colon delivery
CN100340295C (en) 2005-06-29 2007-10-03 山西安特生物制药股份有限公司 Oral administered compound colloid pectin bismuth preparation and its preparing process
ES2279695B1 (en) 2005-08-01 2008-08-01 Jesus Antas Pharma, S.A. NEW SOLID FORMULATIONS OF CAROTENOIDS AND PROCEDURE FOR OBTAINING.
JP4817042B2 (en) 2005-08-26 2011-11-16 国立大学法人三重大学 Method for producing group III nitride crystal containing Al, and group III nitride crystal containing Al
US20070167395A1 (en) 2006-01-17 2007-07-19 Isaac Eliaz Compositions and methods for treating diabetes
KR101234799B1 (en) * 2006-02-07 2013-02-20 삼성전자주식회사 Method and apparatus for controlling movement of robot
KR100912680B1 (en) * 2006-03-16 2009-08-19 (주) 벡스코아 Controlled release formulation
CN101045163B (en) 2006-03-29 2011-03-30 重庆莱美药业股份有限公司 High molecular anticarcinogenic prodrug, its preparing method and use
PT103476B (en) 2006-05-10 2008-09-19 Univ De Coimbra PRODUCTION AND INSULATION PROCESS OF POLYMERIC MICRO- AND NANOPARTICLES CONTAINING MACROMOLECULES OF HYDROFYLIC AND THERMOLIBLE NATURE
CN100394923C (en) 2006-05-26 2008-06-18 范晓青 Application of low molecular citrus pectin in regulation of blood sugar, blood fat and improvement of fatty liver
US20070292480A1 (en) 2006-06-14 2007-12-20 Conopco, Inc., D/B/A Unilever Delivery System for Ingestible Components
MX2009002425A (en) * 2006-09-05 2009-03-20 Astrazeneca Ab Pharmaceutical composition comprising candesartan cilexetil.
BRPI0719319A2 (en) 2006-11-17 2014-02-04 Da Volterra COLONIC RELEASE USING ZN / PECTIN ACCOUNTS WITH AN EUDRAGIT COATING
US20090018175A1 (en) * 2007-04-25 2009-01-15 Itamar Kanari Pharmaceutical excipient complex
EP2172193A1 (en) * 2008-10-02 2010-04-07 Capsulution Nanoscience AG Improved nanoparticulate compositions of poorly soluble compounds
CZ20098A3 (en) 2009-01-13 2010-07-21 Zentiva, K.S. Medicinal forms of tyrosine kinase inhibitors

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5505966A (en) * 1990-07-04 1996-04-09 Kabi Pharmacia Ab Therapeutical composition and process for its preparation
US5849327A (en) * 1994-07-29 1998-12-15 Advanced Polymer Systems, Inc. Delivery of drugs to the lower gastrointestinal tract
US20060188530A1 (en) * 1998-07-24 2006-08-24 Yoo Seo H Bile preparations for gastrointestinal disorders

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
DONALD E. CADWALLADER ET AL: "Effect of macromolecules on aqueous solubility of cholesterol and hormone drugs", JOURNAL OF PHARMACEUTICAL SCIENCES, vol. 70, no. 4, 1 April 1981 (1981-04-01), pages 442 - 446, XP055013096, ISSN: 0022-3549, DOI: 10.1002/jps.2600700426 *
GARCIA ROJAS ET AL: "Cholesterol removal in liquid egg yolk using high methoxyl pectins", CARBOHYDRATE POLYMERS, APPLIED SCIENCE PUBLISHERS, LTD. BARKING, GB, vol. 69, no. 1, 30 March 2007 (2007-03-30), pages 72 - 78, XP022009490, ISSN: 0144-8617, DOI: 10.1016/J.CARBPOL.2006.09.004 *

Also Published As

Publication number Publication date
WO2011063776A2 (en) 2011-06-03
CZ302789B6 (en) 2011-11-09
CZ2009790A3 (en) 2011-06-01
WO2011063776A3 (en) 2012-05-31
WO2011063774A2 (en) 2011-06-03
WO2011063775A2 (en) 2011-06-03
WO2011063775A3 (en) 2012-01-26

Similar Documents

Publication Publication Date Title
WO2014097099A3 (en) Glycoconjugation process
MX2010010647A (en) Process for preparing orally administered dabigatran formulations.
WO2012079092A3 (en) Testosterone undecanoate compositions
WO2010039762A3 (en) Pharmaceutical compositions comprising boronic acid compounds
NZ734152A (en) Compounds, compositions and methods useful for cholesterol mobilisation
MX2011011871A (en) Intravenous formulation with water-soluble cocrystals of acetylsalicylic acid and theanine.
WO2013055899A3 (en) Compositions useful in treating nephropathy and methods for preparation of same
WO2010097243A3 (en) Process for forming solid oral dosage forms of solifenacin and its pharmaceutically acceptable salts
WO2010089361A3 (en) Process for the preparation of a pharmaceutical composition comprising ezetimibe
AR082566A1 (en) LIQUID FORMULATIONS OF ST-246 AND RELATED METHODS, PROCESS
MX2022003486A (en) Therapeutic acid ceramidase compositions and methods of making and using them.
EP2524687A3 (en) Edible jelly-form composition, jelly-form preparation and method for producing jelly-form preparation
WO2012073170A3 (en) Galenic composition suitable for administration to a non-human animal, uses thereof, and associated methods
WO2015034678A3 (en) Corticosteroid containing orally disintegrating tablet compositions for eosinophilic esophagitis
WO2011081373A3 (en) Method for preparing highly pure anhydrous crystalline docetaxel
WO2011063774A3 (en) Pectin complexes of steroids and pharmaceutical compositions based thereon
IN2012DN02576A (en)
TW201129386A (en) Microcrystalline cellulose and calcium phosphate compositions useful as pharmaceutical excipients
GB201309925D0 (en) Preparation method for caspofungin analog
WO2010020799A3 (en) Compositions for the treatment of neoplastic diseases
WO2009155070A3 (en) Compositions and methods for treatment of inflammation and hyperkeratotic lesions
MX2015010486A (en) Chewable composition for oral administration and process for preparing thereof.
WO2011031099A3 (en) Ursodeoxycholic acid-synthetic hydrotalcite-eudragit hybrid, pharmaceutical composition containing the same and method for preparing the same
WO2014006635A3 (en) Solid oral compositions of silodosin
WO2012019428A8 (en) Benzohydrol derivatives, a preparation process and pharmaceutical use thereof

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 10810843

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 10810843

Country of ref document: EP

Kind code of ref document: A2